Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.70    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.10 (3.846%)
Market Cap: £2.78m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

JSOP Award

8 Mar 2019 07:00

RNS Number : 2445S
Litigation Capital Management Ltd
08 March 2019
 

8 March 2019

Litigation Capital Management Limited

("LCM" or the "Company")

 

JSOP Award

 

Litigation Capital Management Limited (AIM:LIT), a leading international provider of litigation financing solutions, announces that it is giving effect to the disclosure made in the Admission document dated 13 December 2018 and has today granted executive director, Nick Rowles-Davies (the "Participant"), an interest over 4,347,517 ordinary shares in the Company, representing 3.85% of the enlarged issued share capital of the Company1, pursuant to a joint share ownership plan ("JSOP").

 

These newly issued ordinary shares will be held by the LCM Employee Benefit Trust ("EBT"), which has been established to hold shares under the JSOP ("JSOP Shares"). The beneficial interest in JSOP Shares is jointly held between the relevant participant and the EBT. Under the JSOP rules, it has been agreed that no voting rights will be exercised on the JSOP Shares prior to their vesting date.

 

A limited recourse loan agreement will be entered into between the Company and both the EBT and Mr. Rowles-Davies. The loan for Mr. Rowles-Davies will be for a term of 10 years and an amount of GBP 217,375.85, which represents market value for Mr. Rowles-Davies interest in the JSOP.

 

The JSOP award to Mr. Rowles-Davies will vest on the third anniversary of the 19th December 2018, subject to continued employment and performance conditions including a share price target of a 175 pence being achieved at any time during the vesting period. In addition, the JSOP award is subject to malus and clawback provisions. The award vests in full in the event of a change of control at any time.

 

Pursuant to the JSOP rules, Mr. Rowles-Davies will benefit from the growth in value of each JSOP Share from the LCM share price on Admission of 52 pence subject to the conditions outlined above.

 

The key benefits of the JSOP are: 

· a real interest in shares for the Participant, which encourages strong individual and Company performance by aligning the interests of Mr. Rowles-Davies with those of the Company and other shareholders;

· provided there is a strong expectation of growth, the JSOP structure lends itself well to the Company's commercial proposal of allowing Mr. Rowles-Davies to enjoy the growth in value of up to c. 3.85% of the issued share capital of LCM.

 

As disclosed in the Company's admission document in December 2018, this award does not count towards any limits applying to the New Share Plans.

 

Application will be made for the 4,347,517 ordinary shares to be admitted to trading on AIM. It is expected that admission will take place on 18 March 2019. Following the allotment and issue, the Company's issued share capital consists of 113,035,446 ordinary shares. The Company does not hold any shares in Treasury, as such the total number of shares in issue with voting rights is 113,035,446.

 

The above figure of 113,035,446 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

1 Share capital enlarged for new issue of shares to the EBT.

 

 

 

CONTACTS

 

 

Litigation Capital Management

 

Patrick Moloney, Chief Executive Officer

 

 

 

 

 

Canaccord (Nomad and Broker)

 

Sunil Duggal / Emma Gabriel

Tel: 020 7523 8000

 

 

Hawthorn Advisors

 

Lorna Cobbett / Zinka MacHale

Tel: 020 3745 4960

lcm@hawthornadvisors.com

 

NOTES TO EDITORS

 

About LCM:

Litigation Capital Management ("LCM") is a leading international provider of litigation financing solutions. This includes single-case and portfolios across; class actions, commercial claims, claims arising out of insolvency and international arbitration. LCM has an unparalleled track record, driven by effective project selection, active project management and robust risk management. Headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

www.lcmfinance.com

 

 

The following notifications are intended to satisfy the Company's obligations under Article 19(3) of EU Regulation No 596/2014 (the Market Abuse Regulation).

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the Person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")

a)

Name

Nick Rowles-Davies

2.

Reason for the notification

a)

Position / status

Executive Director

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Litigation Capital Management Limited

b)

Legal Entity Identifier

213800J2B5SI8F515244

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Jointly held Ordinary Shares

AU000000LCA6

b)

Nature of the transaction

Interest in Ordinary Shares under a Joint Share Ownership

c)

Price(s) and volume(s)

Price(s)

Volume(s)

GBP 217,375.85

4,347,517 shares

 

d)

Aggregated information

- Aggregated volume

- Aggregated price

- Aggregated total

 

N/A - single transaction

e)

Date of the transaction

7 March 2019 (UK)

f)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHJRMJTMBJMTRL
Date   Source Headline
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.